LTR Pharma Limited (ASX:LTP) Adds Indian Patent to Its Men’s Health Portfolio

Aditi Sarkar

11 November 2026 04:33 PM AEDT

LTR Pharma Limited (ASX:LTP) Adds Indian Patent to Its Men’s Health Portfolio

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

• LTR Pharma announced an Indian Patent supporting SPONTAN and ROXUS in a 9 November market release.

• The company develops and commercialises men’s health products, including an on-demand nasal spray for erectile dysfunction.

• FY26 Revenue was approximately AUD 1.62 million, compared with AUD 2.10 million a year earlier.

• Shares gained 5.56% intraday on 11 November, with Volume close to their recent average recently.

A patent announcement in India has brought a new geographic development into view for LTR Pharma Limited (ASX:LTP). The men’s health drug developer announced an Indian patent supporting SPONTAN and ROXUS shortly before its shares rose in trading on 11 November 2026.

Patent Announcement in India

A price-sensitive announcement titled “LTR Secures Indian Patent Supporting SPONTAN and ROXUS” was lodged at approximately 8:52am AEDT on 9 November 2026. The available account identified the announcement title but did not contain the patent’s term, detailed claims or commercial arrangements. An application to quote securities and several directors’ interest notices were also lodged on 6 November.

Men’s Health Development

LTR Pharma researches, develops and repurposes medicines with a focus on men’s health. Its commercialisation work includes a rapid-onset, on-demand nasal spray for erectile dysfunction. The company joined the ASX in December 2023 and has since continued to develop its product portfolio, including the products named in the Indian patent announcement.

Financial Position

For the year ended 30 June 2026, revenue reached approximately AUD 1.62 million, compared with about AUD 2.10 million in FY25. The net loss was around AUD 14.16 million, versus approximately AUD 5.59 million a year earlier. Assets totalled about AUD 20.9 million and liabilities were roughly AUD 0.6 million. Shares issued numbered approximately 182.5 million, putting Market Value near AUD 82 million at the quoted intraday price.

What the Market Data Showed

Shares traded around 47.5 cents near 2:40pm AEDT on 11 November, up 5.56% during the session. Approximately 158,650 shares changed hands, close to the recent daily average of 151,000. The 52-week price range was 35 cents to 75 cents. A patent grant establishes an intellectual property development, while regulatory approvals, distribution and sales remain separate issues. The available information did not confirm a dated next milestone.

FAQs

Q: Which products were named in the patent notice?

A: SPONTAN and ROXUS.

Q: When was the Indian patent release lodged?

A: 9 November 2026.

Q: What did LTR report as FY26 revenue?

A: Approximately AUD 1.62 million.

Q: What is LTR Pharma’s business focus?

A: Men’s health drug development and commercialisation.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.